What is the latest LUPIN stock price?
The latest stored price for LUPIN is Rs 2,201.80 as of 2026-08-21.
gimli
LUPIN stock AI analysis
LUPIN Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
LUPIN LIMITED is a mid-cap stock in Healthcare. This Gimli page shows the latest available LUPIN price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹2,201.80
1W return
-1.49%
1M return
-12.45%
3M return
-3.62%
6M return
-0.79%
1Y return
+12.19%
Market cap
₹100,669.80 cr
PE
14.73
PB
4.47
ROE
+34.34%
ROCE
+22.41%
RSI
29.34
Turnover
₹169.60 cr
Why it can matter in screens
- Momentum: LUPIN is below 50DMA, below 200DMA; RSI is 29.34.
- Returns: 1D +0.01%, 1W -1.49%, 1M -12.45%, 3M -3.62%, 1Y +12.19%.
- Trend levels: 52W high ₹2,529.50, 52W low ₹2,187.70, off high -12.96%.
- Liquidity: latest turnover is ₹169.60 cr; volume vs 20D is +0.66%.
- Valuation/profitability: PE 14.73, PB 4.47, ROE +34.34%, ROCE +22.41%.
- Growth: 3Y sales CAGR +19.10%, 3Y profit CAGR +131.41%.
Quick Answers
Is LUPIN above its 50DMA and 200DMA?
LUPIN is below 50DMA, below 200DMA. The latest 50DMA is 2,376.08 and the latest 200DMA is 2,245.66.
What are LUPIN PE, ROE and ROCE?
LUPIN has PE 14.73, ROE +34.34%, and ROCE +22.41% in Gimli's latest available snapshot.
How has LUPIN performed recently?
LUPIN has returned -12.45% over 1 month, -3.62% over 3 months, and +12.19% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 7,274.38 cr | 3,835.63 cr | 2,714.60 cr | 30.95 |
| 2026-03-31 | 7,391.91 cr | 2,494.95 cr | 1,460.34 cr | 31.96 |
| 2025-12-31 | 7,100.45 cr | 1,949.98 cr | 1,175.55 cr | 25.74 |
| 2025-09-30 | 7,138.00 cr | 2,431.00 cr | 1,485.00 cr | 32.28 |
| 2025-06-30 | 6,163.75 cr | 1,692.75 cr | 1,219.03 cr | 26.70 |
| 2025-03-31 | 5,562.20 cr | 1,378.12 cr | 772.52 cr | 16.93 |
| 2024-12-31 | 5,618.56 cr | 1,409.61 cr | 855.16 cr | 18.75 |
| 2024-09-30 | 5,497.01 cr | 1,382.65 cr | n/a | nan |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 27,487.54 cr | 8,682.54 cr | 5,332.84 cr | 116.75 |
| 2025-03-31 | 22,192.11 cr | 5,479.13 cr | 3,281.62 cr | 71.95 |
| 2024-03-31 | 19,656.34 cr | 3,898.12 cr | 1,914.48 cr | 42.05 |
| 2023-03-31 | 16,269.98 cr | 1,837.39 cr | 430.08 cr | 9.46 |
| 2022-03-31 | 11,988.66 cr | 393.76 cr | -188.70 cr | -4.16 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 38,364.83 cr | 4,167.73 cr | 6,616.18 cr | 22,513.37 cr |
| 2025-03-31 | 29,204.88 cr | 1,930.78 cr | 5,447.77 cr | 17,294.35 cr |
| 2024-03-31 | 23,997.18 cr | 1,187.60 cr | 2,921.77 cr | 14,373.45 cr |
| 2023-03-31 | 22,955.93 cr | 1,277.82 cr | 4,541.52 cr | 12,542.82 cr |
| 2022-03-31 | 21,821.22 cr | 1,089.92 cr | 4,158.38 cr | 12,221.98 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 7,334.50 cr | 5,279.65 cr | n/a |
| 2025-03-31 | 2,999.94 cr | 1,317.51 cr | n/a |
| 2024-03-31 | 3,648.36 cr | 2,719.46 cr | n/a |
| 2023-03-31 | 1,897.24 cr | 397.62 cr | n/a |
| 2022-03-31 | 367.31 cr | -537.77 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +46.85% | +22.42% | +24.65% | +14.84% | +6.08% | +0.00% |
| 2026-03-31 | +46.86% | +21.71% | +25.32% | +16.93% | +6.11% | +0.00% |
| 2025-12-31 | +46.89% | +21.49% | +25.58% | +18.01% | +6.03% | +0.00% |
| 2025-09-30 | +46.90% | +20.49% | +26.55% | +20.57% | +6.06% | +0.00% |
| 2025-06-30 | +46.90% | +21.25% | +25.56% | +19.35% | +6.28% | +0.00% |
| 2025-03-31 | +46.92% | +21.46% | +25.41% | +17.55% | +6.20% | +0.00% |
| 2024-12-31 | +46.95% | +22.04% | +24.74% | +16.92% | +6.26% | +0.00% |
| 2024-09-30 | +46.96% | +21.50% | +25.09% | +16.89% | +6.44% | +0.00% |
| 2024-06-30 | +46.98% | +19.32% | +26.78% | +16.23% | +6.92% | +0.00% |
| 2024-03-31 | +47.01% | +18.28% | +27.76% | +16.82% | +6.93% | +0.00% |
| 2023-12-31 | +47.04% | +16.11% | +29.73% | +18.92% | +7.11% | +0.00% |
| 2023-09-30 | +47.06% | +14.99% | +29.42% | +16.71% | +8.52% | +0.00% |
| 2023-06-30 | +47.07% | +13.94% | +29.36% | +17.00% | +9.63% | +0.00% |
| 2023-03-31 | +47.08% | +13.32% | +29.21% | +16.96% | +10.39% | +0.00% |
| 2022-12-31 | +47.10% | +13.98% | +28.09% | +16.47% | +10.81% | n/a |
| 2022-09-30 | +47.11% | +13.81% | +27.63% | +16.44% | +11.45% | +0.00% |
| 2022-06-30 | +47.10% | +0.29% | +41.16% | n/a | n/a | +0.00% |
| 2022-03-31 | +46.78% | +0.29% | +41.56% | n/a | n/a | +0.00% |
| 2021-12-31 | +46.81% | +0.28% | +40.11% | n/a | n/a | +0.00% |
| 2021-09-30 | +46.83% | +0.28% | +40.12% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
| DRREDDY | DR. REDDY S LABORATORIES | 97,804.91 cr | 29.535819 | +9.23% | -7.98% |
Try these prompts
- Analyze LUPIN with valuation, momentum and industry peers
- Compare LUPIN with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare LUPIN with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.